Fig. 5From: A budget impact analysis of substituting sitagliptin with liraglutide in type 2 diabetes from a private health insurance perspective in EgyptOne-way sensitivity analysis results for sitagliptin. T2DM type 2 diabetes mellitus, CV cardiovascular, PHI private health insurance, DPP4 dipeptidyl peptidase 4, TZD thiazolidinediones, SU sulphonyl urea. The light grey bar corresponds with the upper range, and the dark blue bar with the lower range of an inputBack to article page